News for Aravive, Inc. (ARAV)

PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc.  , a clinical-stage biopharmaceutical company focused on...

Baker Brothers' 13F portfolio value has decreased from $17.35B to $8.79B. Read more to see our updated thesis of the different stakes in the portfolio.

Aravive, Inc. dropped from S&P TMI Index...

PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will...

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.54%

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.35% to 37,398.50 while the NASDAQ rose 1.16% to 15,027.63. The S&P 500 also rose, gaining, 0.67% to 4,770.73.

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.

HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV,

U.S. stocks were lower this morning, with the Dow Jones falling over 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.37% to 35,153.58 while the NASDAQ fell 0.37% to 13,921.89. The S&P 500, also fell, dropping, 0.50% to 4,491.00.

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was ...

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the ...

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective December 31, 2020. This transition will allow Dr. Tabibiazar to focus on a new venture. Dr. Tabibiazar co-founded private Aravive Biologics and served as the Chairman of its board of directors and as President and Chief Executive Officer from its inception to April 2017 and as Executive Chairman from May 2017 until October 2018. During that time, he led Aravive Biologics through a reverse merger with Versartis, Inc., to form the combined company, Aravive, Inc. Dr. Tabibiazar remained on the Board of Aravive, Inc. since October 2018.